Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)

Anna Shalman; Shiri Savir; Yana Mechnik Steen; Andrey Ovanyan; Nancy Boniel; Leonid Koyfman; Yoav Bichovsky; Alexander Zlotnik; Moti Klein; Evgeni Brotfain

doi:10.1016/j.jocn.2020.01.067

Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)

Anna Shalman, Shiri Savir, Yana Mechnik Steen, Andrey Ovanyan, Nancy Boniel, Leonid Koyfman, Yoav Bichovsky, Alexander Zlotnik, Moti Klein, Evgeni Brotfain

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Background: Patients with GBS may develop hypoalbuminemia following treatment with Intravenous Immunoglobulin (IVIG), which is related to a poorer outcome. This report presents a patient with GBS and his clinical response to two courses of IVIG treatments in association with his albumin level. Case report: A previously healthy 21-year-old male was admitted to the GICU due to GBS with severity grade 5 (required assisted ventilation). IVIG treatment was initiated. Over the next two weeks there was no clinical improvement and Albumin level dropped from 4.5 gr/dL to a nadir of 2.3 gr/dL. A second course of IVIG was initiated. After initiation of the second course the patient's albumin began rising to 3.0 gr/dL and a clinical improvement followed this rise. Subsequently, he was weaned from mechanical ventilation within a few days. Conclusions: When considering a second course of IVIG treatment, serum albumin levels may be considered a biomarker as part of the decision algorithm.

Original language	English
Pages (from-to)	247-249
Number of pages	3
Journal	Journal of Clinical Neuroscience
Volume	74
DOIs	https://doi.org/10.1016/j.jocn.2020.01.067
State	Published - 1 Apr 2020

Keywords

Guillain-Barre Syndrome
Hypoalbuminemia
Intravenous Immunoglobulin
Serum albumin

ASJC Scopus subject areas

Surgery
Neurology
Clinical Neurology
Physiology (medical)

Access to Document

10.1016/j.jocn.2020.01.067

Cite this

@article{93b99a785e32433f86f8b59ad4ece4f6,

title = "Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)",

abstract = "Background: Patients with GBS may develop hypoalbuminemia following treatment with Intravenous Immunoglobulin (IVIG), which is related to a poorer outcome. This report presents a patient with GBS and his clinical response to two courses of IVIG treatments in association with his albumin level. Case report: A previously healthy 21-year-old male was admitted to the GICU due to GBS with severity grade 5 (required assisted ventilation). IVIG treatment was initiated. Over the next two weeks there was no clinical improvement and Albumin level dropped from 4.5 gr/dL to a nadir of 2.3 gr/dL. A second course of IVIG was initiated. After initiation of the second course the patient's albumin began rising to 3.0 gr/dL and a clinical improvement followed this rise. Subsequently, he was weaned from mechanical ventilation within a few days. Conclusions: When considering a second course of IVIG treatment, serum albumin levels may be considered a biomarker as part of the decision algorithm.",

keywords = "Guillain-Barre Syndrome, Hypoalbuminemia, Intravenous Immunoglobulin, Serum albumin",

author = "Anna Shalman and Shiri Savir and {Mechnik Steen}, Yana and Andrey Ovanyan and Nancy Boniel and Leonid Koyfman and Yoav Bichovsky and Alexander Zlotnik and Moti Klein and Evgeni Brotfain",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = apr,

day = "1",

doi = "10.1016/j.jocn.2020.01.067",

language = "English",

volume = "74",

pages = "247--249",

journal = "Journal of Clinical Neuroscience",

issn = "0967-5868",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)

AU - Shalman, Anna

AU - Savir, Shiri

AU - Mechnik Steen, Yana

AU - Ovanyan, Andrey

AU - Boniel, Nancy

AU - Koyfman, Leonid

AU - Bichovsky, Yoav

AU - Zlotnik, Alexander

AU - Klein, Moti

AU - Brotfain, Evgeni

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Background: Patients with GBS may develop hypoalbuminemia following treatment with Intravenous Immunoglobulin (IVIG), which is related to a poorer outcome. This report presents a patient with GBS and his clinical response to two courses of IVIG treatments in association with his albumin level. Case report: A previously healthy 21-year-old male was admitted to the GICU due to GBS with severity grade 5 (required assisted ventilation). IVIG treatment was initiated. Over the next two weeks there was no clinical improvement and Albumin level dropped from 4.5 gr/dL to a nadir of 2.3 gr/dL. A second course of IVIG was initiated. After initiation of the second course the patient's albumin began rising to 3.0 gr/dL and a clinical improvement followed this rise. Subsequently, he was weaned from mechanical ventilation within a few days. Conclusions: When considering a second course of IVIG treatment, serum albumin levels may be considered a biomarker as part of the decision algorithm.

AB - Background: Patients with GBS may develop hypoalbuminemia following treatment with Intravenous Immunoglobulin (IVIG), which is related to a poorer outcome. This report presents a patient with GBS and his clinical response to two courses of IVIG treatments in association with his albumin level. Case report: A previously healthy 21-year-old male was admitted to the GICU due to GBS with severity grade 5 (required assisted ventilation). IVIG treatment was initiated. Over the next two weeks there was no clinical improvement and Albumin level dropped from 4.5 gr/dL to a nadir of 2.3 gr/dL. A second course of IVIG was initiated. After initiation of the second course the patient's albumin began rising to 3.0 gr/dL and a clinical improvement followed this rise. Subsequently, he was weaned from mechanical ventilation within a few days. Conclusions: When considering a second course of IVIG treatment, serum albumin levels may be considered a biomarker as part of the decision algorithm.

KW - Guillain-Barre Syndrome

KW - Hypoalbuminemia

KW - Intravenous Immunoglobulin

KW - Serum albumin

UR - http://www.scopus.com/inward/record.url?scp=85079878521&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2020.01.067

DO - 10.1016/j.jocn.2020.01.067

M3 - Article

C2 - 32088107

AN - SCOPUS:85079878521

SN - 0967-5868

VL - 74

SP - 247

EP - 249

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

ER -

Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this